Site-of-Service Cost Differential Debate and 340B Update John Hennessy, MBA, Vice President, Operations, Sarah Cannon Cancer Services Bruce S. Pyenson,

Slides:



Advertisements
Similar presentations
Blending Supply-Side Approaches with Consumerism Paul B. Ginsburg, Ph.D. Presentation to Second National Consumer-Driven Healthcare Summit, September 26,
Advertisements

© Scott & Company, Inc Explaining Retail Clinics, Market Acceptance, Players, Regulators, and the Future of Retail Clinics Legal slides only From.
Healthy Futures Fund Goals 2  PROVIDE NEW CAPITAL to Federally Qualified Health Centers (FQHCs) at a time of significant patient growth  ENCOURAGE COMMUNITY.
INTEGRITY ● ACCESS ● VALUE 1 The 340B Drug Pricing Program: The Basics Paul Shank Health & Human Services Consultant, Health Resources and Services Administration.
Chapter 6 Federal Regulation of Pharmacy Practice.
A Quality Focused, Financially Responsible Approach to Medicaid Reform Jeffrey W. Runge, MD, FACEP NC Medical Society Board of Directors February 11, 2015.
Opportunities to Leverage HIT for Medicaid Reform in New York Rachel Block, United Hospital Fund C. William Schroth, NYS Department of Health eHealth Initiative.
1 1 © 2013 SUNRx and MedImpact, Inc. All Rights Reserved. Confidential, proprietary and possible Trade Secret of SUNRx and MedImpact (See Slide #1) The.
7 th Annual GHA Compliance Officers Retreat September 3 – 5, 2014 Reynolds Plantation Greensboro, Georgia.
340B Drug Pricing Program Annual Recertification for Hospitals
The Patient Protection & Affordable Care Act (ACA) implements broad, historic changes to U.S. health care Expanded access to health insurance and care.
Optimizing The 340B Program Promoting Integrity, Access, & Value To deliver clinically and cost-effective pharmacy services This educational product created.
Britten Pund, Senior Manager, Health Care Access Emily McCloskey, Manager, Policy and Legislative Affairs The Ryan White Program and 340B Pharmacies.
340b Program Background. Proprietary and Confidential. Do not distribute. General Overview What is the 340b program Recent legislative changes and the.
2010 Legislation and Health Care Reform; How it will affect dentistry?
Tracey Moorhead President and CEO May 15, 2015 No Disclosures ©AAHCM.
Major Health Issues The Affordable Healthcare Act.
Physician Leader Perspective of ACO Transition Scott D. Hayworth, MD, FACOG President and CEO Mount Kisco Medical Group, PC.
Capacity Task Force Virginia Health Reform Initiative January 14, 2011
1 Managed Care Digest Series ®, © 2013 sanofi-aventis U.S., A SANOFI COMPANY Data source: IMS Health © 2013 US.NMH Practice and Hospital Site.
Notice of Privacy Practices Nebraska SNIP Privacy Subgroup July 18, 2002 Michael J. Brown, MHA, CPA Vice-President, Administrative & Regulatory Affairs,
Hospital/Healthcare Provider Analysis 7/9/15. HCA owns and operates approximately 166 hospitals and approximately 113 freestanding surgery centers in.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
340B: An Overview.
Global Healthcare Trends
HEALTHCARE TRUSTEES OF NEW YORK STATE Compliance and Governance Update August 8, 2012.
Serving America's Veterans: How Florida Health Centers Can Answer the Call Florida Association of Community Health Centers Webinar 08/19/2015 3pm, EST.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
THE COMMONWEALTH FUND Developing Innovative Payment Approaches: Finding the Path to High Performance Stuart Guterman Assistant Vice President and Director,
AMA’s National Managed Care Contract and Database Wes Cleveland, JD American Medical Association
An Integrated Healthcare System’s Approach to ACOs Chuck Baumgart, M.D., Chief Medical Officer Presbyterian Health Plan David Arredondo, M.D., Executive.
The Rolling Hills Group Creating the Plan for Healthcare Reform for Tennessee.
1. Oncologist-Hospital Alignment: Implementing the Relationship  Ronald Barkley, MS, JD, CCBD Group  Teri Guidi, MBA, FAAMA, Oncology Management Consulting.
Getting Connected: Can the ACA Improve Access to Health Care in Rural Communities? Russell Senate Office Building October 13, 2010 Clint MacKinney, MD,
Computerized Networking of HIV Providers Workshop Data Security, Privacy and HIPAA: Focus on Privacy Joy L. Pritts, J.D. Assistant Research Professor Health.
Accelerating Care and Payment Innovation: The CMS Innovation Center.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Understanding Federally Qualified Health Centers and Federally Qualified Health Center Look-Alikes Tonya Bowers, MHS Department of Health and Human Services.
THE COMMONWEALTH FUND Matching Revenue Flows With Population Needs: The Challenge of Payment Variation Across Providers and Payers and Over Time Stuart.
EHealthUniversity1 Virtual Health Center, Inc PHS 340B Pricing Program August 21, 2014 Dr. Erica Watkins,PharmD, RPh Vice President, Business Development.
340B PRICING AND PROCUREMENT ELIGIBILITY, ENROLLMENT, AND REQUIREMENTS Virtual Health Center’s eHealthUniversity Dr. Erica C. Watkins, PharmD, RPh August.
National Rural Health Association November  Rural programs fighting for survival, today, originated from historic challenges ◦ Critical Access.
Optimizing The 340B Program Promoting Integrity, Access, & Value To deliver clinically and cost-effective pharmacy services This educational product created.
Cost Drivers of Cancer Care: Medicare and Commercially Insured Populations Pamela Pelizzari April 1, 2016.
Office of Pharmacy Affairs 340B Drug Pricing Program Bradford R. Lang JD, MPH Public Health Analyst US Dept. of Health and Human Services Health Resources.
340B Update David Pointer, President SolutionsRx HFMA Joint Fall Conference (Show-Me, Heart of America, Greater St. Louis Chapters) October 23, 2015 Mega.
Understanding Community Cancer Care.  Historically, cancer care occurred predominantly in hospital setting  A few decades ago, care migrated to the.
MEDICATION USE IN RURAL AMERICA ASSOCIATION UPDATES National Community Pharmacists Association Tina Schlecht, PharmD, MBA Director, Pharmacy Affairs.
PREPARED BY: SUZAN BRUCE, CPC CLINICAL TRIALS OFFICE, UC DAVIS 1 Clinical Research Billing & Coding.
Community-based Care Transitions Program (CCTP) Juliana R. Tiongson Social Science Research Analyst Centers for Medicare and Medicaid Services Office of.
AFFORDABLE CARE ACT: OVERVIEW, STUDY OF THE GENERAL EFFECTS ON RADIOLOGY, HOW FAR HAVE WE COME AND THE FUTURE Bhavya Rehani, MD, Lindsay P. Busby, MD,
CRITICAL ACCESS HOSPITALS. Balanced Budget Act of 1997 The BBA had a severe financial impact on hospitals around the country. To help alleviate the impact.
Personal Finance. 2 What is risk? Uncertain and unpredictable factors, some of which can be controlled to a certain extent, that can lead to loss or injury.
Hospital Pricing Mike Del Trecco, Senior Vice President of Finance, Finance and Operations Senate Finance Committee February 9, 2017.
340 B Program Where do we go from here?
Proposed Medicaid Hospital Outpatient Prospective Payment System
The Institution and HTC 340B Program Relationship
Managing Antitrust Risks in
Hemophilia Alliance Fall Meeting 2017
Using an Episode-based payment model to improve oncology care
340B: Overview of the Program and Legislative Update
67th Annual HSFO Conference Louisville, KY
Accountable care organizations
OHA update Ohio Hospital transparency
OHA update Ohio Hospital transparency
LEVERAGING PURCHASED/REFERRED CARE (PRC) RATES
Value-Based Healthcare: The Evolving Model
Community Oncology 101: WHY DOES SITE OF SERVICE MATTER?
Leadership State of the Alliance
Ryan Witz VP, Healthcare Financing Initiatives
Presentation transcript:

Site-of-Service Cost Differential Debate and 340B Update John Hennessy, MBA, Vice President, Operations, Sarah Cannon Cancer Services Bruce S. Pyenson, FSA, MAAA, Principal and Consulting Actuary, Milliman Erich Mounce, MHA, Chief Executive Officer, The West Clinic Paul O’Dea, Vice President Hospital Business, McKesson Specialty Health Dan Todd, Former Health Policy Advisor, Senate Finance Committee Elizabeth S. Elson, Of Counsel, Foley & Lardner LLP

Site-of-Service Cost Differential Debate and 340B Update Bruce S. Pyenson, FSA, MAAA, Principal and Consulting Actuary, Milliman

Chemotherapy Site of Service and Payer Cost: Where is Payment Reform? Bruce Pyenson, FSA, MAAA Principal & Consulting Actuary November, 2014

5 Bruce Pyenson Milliman, NY. November 2014 Disclosure Pyenson is employed by Milliman, Inc.  Some of the material presented here was funded by Genentech (2013), Inc. and US Oncology, Inc. (2011)  Recent work for many insurers, pharmaceutical companies, device makers, advocacy groups, ACOs  Reports with full details available from me: or  My opinions and results of my analysis, not necessarily Milliman’s

6 Bruce Pyenson Milliman, NY. November 2014 Chemotherapy Cost and Site of Service  Significant cost on a population basis –Episode of chemotherapy for commercial payers are approaching $100,000 –Under 0.25% of population, but accounts for about ~5% of total cost  Chemotherapy delivered in Hospital OP costs are much higher than Physician office –28% higher for adjuvant colorectal cancer –53% higher for metastatic breast cancer –Similar situation for NSCLC and breast cancer  Hospitals are buying oncology practices because they are profitable for the hospital –Several considerations including 340B pricing

7 Bruce Pyenson Milliman, NY. November 2014 Chemo Patients are More Expensive! Milliman analysis of 2008 Medstat MarketScan with about 30 million commercially insured lives

8 Bruce Pyenson Milliman, NY. November 2014 Questions About the Future?  How will payers respond to higher cost of hospital outpatient chemotherapy? –Limited networks? –Limited reimbursement?  How will ACOs deal with chemotherapy? –ACOs are mostly dominated by hospitals –The higher prices of oncology practices become a liability to ACOs under shared savings, capitation or bundled payments  Is chemo in physician offices a winner for bundled payments? –Shared savings relative to benchmark Medicare spending –Does benchmark include more expensive hospital outpatient services?

9 Bruce Pyenson Milliman, NY. November 2014 Healthcare Reform is Changing Everything In most countries around the world… A period of experimentation as favored policy theories are adopted by governments Focus on reversing decades of automatic spending increases Change is certain and Fast.

10 Bruce Pyenson Milliman, NY. November 2014 Comparing Oncology Cost in Community (Physician Office) and Hospital Outpatient Settings  Huge payer databases are ideal for the HOP / PO comparison.  Earlier studies found that payer oncology costs were higher in Hospital outpatient than physician office settings. But consideration of severity differences were not examined.  Milliman did attempt to address severity differences by separating metastatic and adjuvant patients based on the therapies they received

11 Bruce Pyenson Milliman, NY. November 2014 Accounting for Differences in Severity  Truven MarketScan™ claims data…over 40 million commercial insured lives  large sample size  Patients whose chemotherapy began in  3 cancers which account for ~54% of chemotherapy patients

12 Bruce Pyenson Milliman, NY. November 2014 Cost Higher in Hospital OP Setting

13 Bruce Pyenson Milliman, NY. November 2014 Higher Costs for Chemotherapy Agents

14 Bruce Pyenson Milliman, NY. November 2014 Details of Higher Cost for mCRC in HOP  Biologic, cytotoxic, radiation therapy, and other

15 Bruce Pyenson Milliman, NY. November 2014 What About the Future? Payer Perspective Possible effects  More bargaining power from larger organizations—upward pressure on prices  Pathways being enforced by ACO instead of payer as risk shifts to ACO  Participation—or exclusion—from limited networks  Referral management—ACO will control which providers get patients

340B Drug Pricing Program Update Elizabeth Elson Of Counsel Foley & Lardner LLP

340B Drug Pricing Program Overview Federal drug pricing program Operated by the Office of Pharmacy Affairs (“OPA”) in the Health Resources and Services Administration (“HRSA”) Drug manufacturers are required to provide significant discounts to participating covered entities on covered outpatient drugs Covered entities include health care providers such as FQHCs, specialized clinics, and DSH hospitals (with DSH > 11.75%) Intended to provide financial relief to facilities that provide care to the medically underserved

ACA’s Impact on 340B Drug Pricing Program Affordable Care Act expanded participation to new covered entities: Children's hospitals with Medicare DSH > 11.75% Freestanding cancer hospitals with Medicare DSH > 11.75% Critical access hospitals (CAHs) Rural referral centers with a Medicare DSH > 8% Sole community hospitals with a Medicare DSH > 8% It also created increased program integrity efforts (e.g., annual recertification, increased auditing) and new sanction authority for compliance violations

Means of Obtaining 340B Discounts Hospital Provider-Based Clinics Clinics listed as reimbursable cost centers on a 340B Hospital’s most recently filed Medicare cost report may access 340B Drugs Clinics must be licensed and operated as part of 340B Hospital; must also be registered with HRSA as child sites of 340B Hospital Referral Arrangements Documented referral arrangements by 340B covered entity to non- provider-based clinics consistent with Apexus guidance MD Office not eligible for 340B purchasing

Provider-Based Clinics Clinics must meet certain requirements such as: – Licensure as part of 340B Hospital – Financial integration with Hospital – Clinical integration with Hospital – Oversight and supervision by Hospital – Location (35 mile rule unless exempted) – Public awareness of clinic as part of Hospital Certain hospital within hospital or joint venture type arrangements may provide access to 340B if provider-based rules met

Future of 340B Program Increased government and manufacturer scrutiny HRSA’s anticipated “Mega Regs” Ongoing orphan drug litigation related to ACA provision’s expansion of covered entities; potential impact on “Mega Regs” Questions about how the current political environment will impact future of 340B Program

Contact Information: Elizabeth Elson Foley & Lardner LLP (213)